Allouche Cyril 4
4 · Revance Therapeutics, Inc. · Filed Nov 16, 2018
Insider Transaction Report
Form 4
Allouche Cyril
Principal Financial Officer
Transactions
- Tax Payment
Common Stock
2018-11-15$20.99/sh−259$5,436→ 4,491 total
Footnotes (1)
- [F1]Represents the number of shares withheld by and surrendered to the issuer on November 15, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of a 2016 Restricted Stock Award ("RSA") for 3,000 shares. The RSA vests in four equal annual installments from November 15, 2016, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.